Imgatuzumab
Imgatuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Roche.
Mechanism of Action[edit]
Imgatuzumab works by binding to the epidermal growth factor receptor (EGFR), which is overexpressed in many types of cancer. By binding to EGFR, imgatuzumab inhibits the growth and proliferation of cancer cells.
Clinical Trials[edit]
Imgatuzumab has been tested in several clinical trials for various types of cancer, including colorectal cancer, lung cancer, and head and neck cancer. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.
Side Effects[edit]
Like all drugs, imgatuzumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and rash. In rare cases, imgatuzumab can cause serious side effects, such as lung disease and heart problems.
Future Research[edit]
Research is ongoing to determine the best use of imgatuzumab in cancer treatment. This includes determining which types of cancer respond best to the drug, as well as identifying potential biomarkers that can predict a patient's response to imgatuzumab.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
